SK Bioscience eyes Europe as market for COVID-19 vaccine

SK Bioscience has submitted the application for conditional approval of the COVID-19 vaccine SKY Covione with the European Medicines Agency in efforts to expand its presence in the global market, the South Korean vaccine developer said Monday. Beginning with the European region, SK Bioscience said it will look to showcase the South Korean COVID-19 vaccine on the global stage as the size of the coronavirus vaccine market grows rapidly. South Korea’s Ministry of Food and Drug Ministry gave the green light to SKYCovione at the end of June as the country became the third nation in the world with a homegrown COVID-19 treatment and a domestically-developed vaccine, behind the UK and US.